2 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Refractory Cancer: new trials by email Literature Review of Refractory Cancer trials Research Report on Refractory Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody HST-1011, Cemiplimab - Solid Tumor, Adult, Relapsed Cancer | Phase 1 / Phase 2 | Active not recruiting | HotSpot Therapeutics, Inc | 77 | 2023-03-15 | 2025-02-04 |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor IMA401 (Phase Ia), Pembrolizumab (Phase Ia), IMA 401 (Phase Ib) - Refractory Cancer, Recurrent Cancer | Phase 1 | Active not recruiting | Immatics Biotechnologies GmbH | 95 | 2022-05-19 | 2026-04-30 |
Neoplasms (2) · Recurrence (2)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
cemiplimab (1) · pembrolizumab (1) · spartalizumab (1)
HotSpot Therapeutics, Inc (1) · Immatics Biotechnologies GmbH (1)
Canada (1) · Germany (1) · Spain (1) · United States (1)
2023 (1)